Payment overview · 2025
General Payments
$122.72
2 reported records · 2 companies
Healthcare provider profile · identity verified
Muhammad Muzammil, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ITASCA, IL · NPI 1558320879
Verified facts
What the public records show
CMS Open Payments records show Muhammad Muzammil, MD received $122.72 in general payments during 2025 across 2 reported records.
GlaxoSmithKline, LLC. accounted for 83.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $102.34 | 83.4% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $20.38 | 16.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $122.72 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $102.34 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 785 | 206 |
| Amlodipine Besylate | Amlodipine Besylate | 532 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 439 | 109 |
| Omeprazole | Omeprazole | 370 | 104 |
| Metformin Hcl | Metformin Hcl | 358 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 345 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 273 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 270 | 85 |
| Losartan Potassium | Losartan Potassium | 247 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 244 | 69 |
| Furosemide | Furosemide | 241 | 65 |
| Lisinopril | Lisinopril | 237 | 66 |
| Eliquis | Apixaban | 235 | 39 |
| Gabapentin | Gabapentin | 215 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 212 | 54 |
| Jardiance | Empagliflozin | 178 | 26 |
| Finasteride | Finasteride | 151 | 40 |
| Sertraline Hcl | Sertraline Hcl | 142 | 35 |
| Montelukast Sodium | Montelukast Sodium | 140 | 35 |
| Alprazolam | Alprazolam | 127 | 41 |
| Famotidine | Famotidine | 124 | 24 |
| Simvastatin | Simvastatin | 122 | 32 |
| Carvedilol | Carvedilol | 117 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 114 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 105 | 28 |
| Tramadol Hcl | Tramadol Hcl | 104 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 101 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 50 |
| Clonazepam | Clonazepam | 95 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 85 |
| Potassium Chloride | Potassium Chloride | 93 | 30 |
| Spironolactone | Spironolactone | 90 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 22 |
| Alendronate Sodium | Alendronate Sodium | 84 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 18 |
| Lorazepam | Lorazepam | 80 | 18 |
| Allopurinol | Allopurinol | 79 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 13 |
| Mirtazapine | Mirtazapine | 78 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 16 |
| Glipizide | Glipizide | 74 | 22 |
| Prednisone | Prednisone | 74 | 54 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 63 |
| Donepezil Hcl | Donepezil Hcl | 68 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 14 |
| Levetiracetam | Levetiracetam | 61 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 48 |
| Trazodone Hcl | Trazodone Hcl | 61 | 13 |
| Metformin Hcl Er | Metformin Hcl | 60 | 20 |
| Ozempic | Semaglutide | 60 | 13 |
| Azithromycin | Azithromycin | 59 | 47 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 31 |
| Meloxicam | Meloxicam | 58 | 29 |
| Bumetanide | Bumetanide | 57 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 24 |
| Ezetimibe | Ezetimibe | 56 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 18 |
| Latanoprost | Latanoprost | 50 | suppressed |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | suppressed |
| Celecoxib | Celecoxib | 43 | 12 |
| Glimepiride | Glimepiride | 43 | suppressed |
| Tradjenta | Linagliptin | 43 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 34 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | 11 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | 15 |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 12 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | 19 |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 27 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Pentasa | Mesalamine | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Nystatin | Nystatin | 23 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Carbamazepine Er | Carbamazepine | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Cholestyramine Light | Cholestyramine | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Ramipril | Ramipril | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 15 |
| Diazepam | Diazepam | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Olanzapine | Olanzapine | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Daptomycin | Daptomycin | 14 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 12 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $122.72 · 2 records | GlaxoSmithKline, LLC. | AURYON LASER SYSTEM 100-120 VAC, BENLYSTA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error